EP Patent

EP4257138A3 — Improved protocol for treatment of lupus nephritis

Assigned to Aurinia Pharmaceuticals Inc · Expires 2024-01-03 · 2y expired

What this patent protects

By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.

USPTO Abstract

By employing a pharmacodynamic dosing regimen, the effectiveness of a protocol for treatment of a proteinuric kidney disease with voclosporin can be maximized while minimizing undesirable side effects.

Drugs covered by this patent

Patent Metadata

Patent number: EP4257138A3
Jurisdiction: EP
Classification: —
Expires: 2024-01-03
Drug substance claim: No
Drug product claim: No
Assignee: Aurinia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.